Every year, approximately 700 Canadians are diagnosed with chronic myeloid leukemia (CML), a type of blood cancer that starts in the bone marrow. While there is no cure, people with CML today have a ...

Single-cell analysis of CML patients bone marrow at diagnosis reveals coexistence of CD26-CD35+ healthy stem cells and CD26+CD35- CML stem cells, and how the ratio between these impacts TKI response.

The ASH Annual Meeting is one of the largest gatherings of the international hematology community, aggregating the latest scientific research on the pathogenesis and clinical treatment of hematologic ...

The S&P/ASX 200 Information Technology sector fell 4.43% in October but leads ASX sectors YTD, up 41.95% Global X investment ...

More than $994 million has been raised by Cambridge technology companies in the past 12 months (to October 16, 2024) – helped ...

Chase Mining Corporation Limited (AU:GCM) has released an update. Chase Mining Corporation Limited has acquired an innovative technology to ...

Basel, October 29, 2024 – Novartis announced today that Scemblix ® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed ...

Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III trial ...

Cunningham Mining Ltd (“CML”) has entered into a definitive arrangement agreement with American Creek ... efficient, and accessible. As blockchain technology continues to revolutionize industries, RWA ...

Assam, has taken a significant step towards ensuring sustainable water supply for future generations by signing two Memorandum of Understandings (MoUs). The first MoU is with the Centre for ...

For most of the last few decades, AI has over-promised and under-delivered. However, behind the scenes, very significant advances in deep learning technologies have had a revolutionary impact within ...

OKYO Pharma has initiated the Phase II trial of OK-101, a treatment for neuropathic corneal pain (NCP), by dosing the first ...